Long before the headlines about coin-sized implants, a small square of silicon smaller than a fingernail was already letting paralyzed people move cursors and control robotic arms with their thoughts. It has been doing so for two decades, mostly out of the spotlight.
Key takeaways
- Blackrock Neurotech's Utah Array (犹他阵列) has been implanted in humans since 2004 and underlies most human BCI research.
- The company's MoveAgain system earned FDA Breakthrough Device designation in 2021 but is not yet a commercially approved product.
- In 2024, stablecoin issuer Tether invested US$200 million, becoming the majority stakeholder.
- Blackrock sells an ecosystem — electrodes, hardware, and software — rather than a single consumer device, and emphasizes longevity over headline speed.
The array almost everyone uses
The Utah Array is a grid of sharp silicon electrodes, invented by Richard Normann at the University of Utah, that records the firing of many individual neurons at once. A standard array holds 96 electrode channels, a specification that served as the workhorse for invasive BCI for nearly two decades. Blackrock Neurotech describes it as the world's most advanced and longest-lasting intracortical electrode, and notes that nearly all BCIs implanted in humans have used its technology. That is a striking claim, but it holds up in the literature: the same arrays sat at the core of the BrainGate demonstrations, the Stanford speech study, and countless research implants. The company cites more than 30,000 cumulative days implanted across human studies and over 2,000 published studies built on its platform.
From research tool to company
Blackrock's story is less a startup founding than a long consolidation. Blackrock Microsystems was founded in 2008 and that year acquired the research business of Cyberkinetics Neurotechnology Systems, the company behind the original BrainGate system. In 2021 the business rebranded as Blackrock Neurotech to reflect its focus on clinical translation. The Utah Array itself predates the company: it has been implanted in humans since 2004, a track record of biocompatibility and stability that newer entrants are still working to match.
MoveAgain and the FDA pathway
The company's lead medical product is MoveAgain, a BCI system intended to let immobile patients control a mouse cursor, keyboard, mobile device, tablet, wheelchair, or prosthetic simply by thinking. In November 2021, the U.S. FDA granted MoveAgain Breakthrough Device designation, a program that speeds review of technologies for irreversibly debilitating conditions. It is worth being precise: designation is not approval. MoveAgain remains, in the company's own wording, an "upcoming" product, and the 2021 goal of commercialization in 2022 did not materialize. The designation signals promise and a faster regulatory lane, not a cleared therapy on the shelf.
The Tether deal
In April 2024, stablecoin issuer Tether announced a US$200 million strategic investment in Blackrock Neurotech through a newly formed venture arm, Tether Evo. The deal made Tether the majority stakeholder. The funding was framed as supporting commercialization of Blackrock's medical products and research and development. For a field where most players are venture-backed and pre-revenue, a nine-figure check from an unexpected source underlined how seriously neural interfaces are now being capitalized — and how unusual the roster of backers has become.
Why a quiet backbone matters
Blackrock's value is not one splashy demo but consistency. Its ecosystem approach — implantable electrodes plus the headstages, signal processors, and software that turn neural spikes into usable commands — is why labs around the world trust it. Demonstrated uses of its technology include surfing the web, sending messages, creating digital art, and even controlling a robotic arm well enough to feel it as one's own through sensory feedback. That breadth is the unglamorous foundation on which the newer, faster, wireless implants are being built.
Honest limitations
Blackrock's hardware is proven but aging in design terms: rigid silicon arrays with a percutaneous connection are less comfortable and lower-channel than the newest flexible threads. MoveAgain is still not an approved commercial product, so patients cannot simply obtain it. And the Tether investment, while large, ties a medical-technology company's majority ownership to a cryptocurrency issuer, a structure with little precedent and unknown long-term implications. The field's hype often outruns what any single company has actually shipped to patients.
What readers can do now
- If you follow neurotechnology investing, read funding announcements against the regulatory status — a majority sale is not the same as a product approval.
- For clinicians and researchers, Blackrock's published track record is a useful benchmark when evaluating newer implant claims.
- For patients, the practical takeaway is sobering but important: proven, approved at-home BCI is not yet widely available, so discuss established assistive options with your care team first.
A trend note
According to Li An, chief scientist at BrainNet (脑机网), the companies that endure in this field will be those that pair durable, well-characterized hardware with a clear clinical pathway, not those with the loudest launch.